Navigation Links
Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
Date:10/22/2007

NATICK, Mass., and WASHINGTON, Oct. 22 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today welcomed results from the SPIRIT III Clinical Trial, which continue to support the proven safety and efficacy of the market-leading TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System and add to the growing body of strong clinical evidence for the XIENCE(TM) V (PROMUS(TM)) Everolimus Eluting Coronary Stent System. An analysis of the data was presented by Gregg W. Stone, M.D., of Columbia University Medical Center and the Cardiovascular Research Foundation in New York, and the Principal Investigator of the SPIRIT III Trial, during a late- breaking trial session at the Cardiovascular Research Foundation's (CRF) nineteenth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C.

One-year results from the SPIRIT III trial included an updated analysis of 1,002 patients with coronary artery disease treated with either the XIENCE V (PROMUS) Stent or the TAXUS Express Stent. Ischemia-driven target lesion revascularization (TLR) for 669 patients treated with the XIENCE V (PROMUS) Stent changed from 2.6% to 3.3% between nine months and one year, while for the 333 patients treated with the TAXUS Stent, TLR changed from 5.0% to 5.6% during the same time period, still failing to reach statistical significance (p=0.09). Target vessel revascularization (TVR) at one year was also similar, with 6.1% for PROMUS and 7.5% for TAXUS (p=0.41).

The overall MACE (Major Adverse Cardiac Events) rate (defined as cardiac death, myocardial infarction (heart attack, or MI) or ischemia-driven TLR) through one year was 5.8% for the XIENCE V (PROMUS) Stent and 9.9% for the TAXUS
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Boston Scientific Announces Schedule for EuroPcr 2007
2. Boston Life Sciences, Inc. Announces Presentation of Cethrin Phase I/IIa 6-Month Results at 75th Annual Meeting of the American Association of Neurological Surgeons
3. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
4. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
5. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
6. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
7. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
10. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
11. Inspire Announces Presentations at Two European Scientific Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 BreedIT Corp (OTC: BRDT), ... distributor of highly sophisticated agro-breeding solutions for plant breeders ... the Company,s board of directors appointed chemistry and pharmaceutical ... new member of the board. From 1975 ...
(Date:1/15/2014)... 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ... System as a non-invasive, wireless continuous glucose monitoring system, ... Chairman and Interim CEO of Echo Therapeutics, will present ... Conference. Mr. Doman will make a ...
(Date:1/15/2014)... Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... tender offer by its indirect wholly-owned subsidiary, Sapphire Subsidiary ... common stock of Solta Medical, Inc. (NASDAQ: ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... , May 25 A record 235 new ... being developed by America,s pharmaceutical research and biotechnology companies, according to a ... , , ... adult population suffers from diabetes—a rate that has more than doubled since ...
... HELMOND, The Netherlands , May 25, 2010 Blue Medical ... life of,patients with cardiovascular disease, with the start of the PIONEER trial, in,which ... , , ... clinical program, is the trial that,enables for the first time the delivery of ...
Cached Medicine Technology:New Report Shows Record Number of Medicines Currently in Development to Treat Diabetes 2New Report Shows Record Number of Medicines Currently in Development to Treat Diabetes 3New Report Shows Record Number of Medicines Currently in Development to Treat Diabetes 4First Coronary Stent on Drug Eluting Balloon Implanted 2
(Date:4/15/2014)... RECIST Working Group published in the European Journal of ... categorization of tumor response or various aspects of progression could ... They found that modeling target lesion tumor growth did not ... of the other components of progression. The RECIST Working Group ...
(Date:4/14/2014)... been made in chemotherapy over the past decade, but ... continues to be a major challenge. , Nanotechnology ... the use of nanocarriers, or capsules, that can transport ... body. , The catch? These carriers are tiny, and ...
(Date:4/14/2014)... Henry Ford Hospital reached a medical milestone April 3, ... novel way to access the heart. , Henry Ford ... the unique procedure called transcaval valve replacement, which accesses ... Northern Michigan resident Viola Waller, 80, underwent Henry Ford,s ...
(Date:4/14/2014)... , , Penicillin, one of the scientific marvels of the ... it once won against bacterial infections. But scientists at ... new approach to restoring its combat effectiveness, even against ... the power of the penicillin family of drugs since ...
(Date:4/14/2014)... an active role in their radiation treatment decisions leaves ... may even relieve psychological distress around the experience, researchers ... University of Pennsylvania report in the journal ... undergoing radiation treatment, Neha Vapiwala, MD , an ...
Breaking Medicine News(10 mins):Health News:Can refined categorization improve prediction of patient survival in RECIST 1.1? 2Health News:Nano shake-up 2Health News:Henry Ford Hospital hits new heart valve surgery milestone 2Health News:Penicillin redux: Rearming proven warriors for the 21st century 2Health News:Penicillin redux: Rearming proven warriors for the 21st century 3Health News:Shared decision making during radiation therapy improves patient satisfaction 2Health News:Shared decision making during radiation therapy improves patient satisfaction 3
... Each year the American Institute of Biological Sciences ... contributions to the biological sciences. The AIBS ... to announce the following award winners for 2009: ... PhD, University of Washington, Outstanding Service Award: Robert ...
... Calif., May 15 Cord Blood America, Inc. (OTC ... preservation company ( http://www.cordblood-america.com ) ... cells to families nationwide and internationally, said today that ... In audio interview with analyst Francis Gaskins, explains the ...
... 15 The YWCA USA presented its prestigious 2009 ... Justice and YWCA Niagara for Women,s Economic Advancement at ... Washington, D.C. They were selected among six exemplary initiatives ... , , YWCA Central Massachusetts was honored ...
... Cigna Medical Group has announced the opening of its ... the total number of CareToday clinics to six.CareToday Anthem ... Daisy Mountain Drive and Gavilan Peak Parkway, 39510 North ... practitioners and physician assistants, the clinics offer after hours ...
... to be the fourth fatality in the U.S. , , FRIDAY, ... the swine flu outbreak has yet to run its current ... schools were closed Thursday after dozens of flu-like infections surfaced ... ventilator, according to published reports. , Meanwhile, a woman in ...
... with trastuzumab (Herceptin) to treat women who have metastatic ... their treatment options. , At the 45th Annual Meeting ... (ASCO), researchers from the Mayo Clinic campus ... vinorelbine, and trastuzumab offers a treatment option that is ...
Cached Medicine News:Health News:AIBS honors outstanding contributions to biology 2Health News:AIBS honors outstanding contributions to biology 3Health News:AIBS honors outstanding contributions to biology 4Health News:AIBS honors outstanding contributions to biology 5Health News:Cord Blood America CEO Matthew Schissler Expands on Thought Process in Owning Stem Cell Laboratory 2Health News:Cord Blood America CEO Matthew Schissler Expands on Thought Process in Owning Stem Cell Laboratory 3Health News:YWCA USA 2009 Hallmark Initiative Awards Presented to YWCA Central Massachusetts and YWCA Niagara 2Health News:Cigna Medical Group Announces Grand Opening of CareToday Clinic in Anthem, Ariz. 2Health News:Swine Flu Closes Three Schools in NYC 2Health News:Swine Flu Closes Three Schools in NYC 3Health News:Swine Flu Closes Three Schools in NYC 4Health News:Swine Flu Closes Three Schools in NYC 5Health News:Swine Flu Closes Three Schools in NYC 6Health News:Swine Flu Closes Three Schools in NYC 7Health News:Swine Flu Closes Three Schools in NYC 8Health News:Swine Flu Closes Three Schools in NYC 9Health News:Triple drug combination is promising option to treat metastatic HER2+ breast cancer 2Health News:Triple drug combination is promising option to treat metastatic HER2+ breast cancer 3
Shafts angled 45 degrees, 10 mm from tip to bend. 1 x 2 teeth. Serrated handle with polished finish. Most popular size or model....
Straight shafts with 5.5 mm tying platform and 1 mm crisscross serrated tips. Wide serrated handle with polished finish....
Serrated tips, straight platforms....
Curved shafts with fine pointed tips. Smooth handle with dull finish....
Medicine Products: